Tavexia Lifecare to Acquire 60% Stake in Meyonex Pharmaceuticals for ₹67.19 Crore
Sattva Sukun Lifecare Ltd · Outcome · 08 Oct 2026, 4:13 am
Tavexia Lifecare to Acquire 60% Stake in Meyonex Pharmaceuticals for ₹67.19 Crore Tavexia Lifecare's Board approved the acquisition of a 60% controlling stake in unlisted Meyonex Pharmaceuticals on 7th Oct'26 for an all-cash consideration of ₹67.19 Cr. The company will subscribe to 2,09,97,180 fresh equity shares at an issue price of ₹32 per share. To finance the acquisition, the Board granted in-principle approval to raise funds through the issuance of securities, including equity, warrants, or debt, via preferential allotment or rights issue. Meyonex reported FY25 turnover of ₹10.79 Cr compared to ₹13.32 Cr in FY24.
Original exchange filing (PDF)
More announcements from Sattva Sukun Lifecare Ltd
- Financial Result · 05 Nov 2026
- Announcement · 05 Nov 2026
- Board has Approved in Change in RTA · 05 Nov 2026
- Result · 05 Nov 2026
- Outcome of Board Meeting · 05 Nov 2026
- Tavexia Lifecare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve Intimation of Board Meeting · 04 Nov 2026
- Announcement · 13 Oct 2026
- Disclosure under regulation 30 · 12 Oct 2026
